Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 4

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
less option exercises and vesting of restricted stock(262)— — (19,221)— — (19,221)Repurchase of common stock in connection with Stock Repurchase Program(1,482)— — (103,018)— — (103,018)Stock-based compensation— — 19,427 — — — 19,427 Vesting of RSAs in connection with ESPP— — 3,449 — — — 3,449 Other comprehensive income, net of tax— — — — 1,599 — 1,599 Net income— — — — — 35,149 35,149 Balance at June 30, 2025105,288 $138 $900,864 $(866,931)$2,291 $599,431 $635,793 Issuance of common stock under incentive award plan640 1 9,943 — — — 9,944 Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(194)— — (13,895)— — (13,895)Repurchase of common stock in connection with Stock Repurchase Program(610)— — (42,464)— — (42,464)Stock-based compensation— — 20,386 — — — 20,386 Vesting of RSAs in connection with ESPP— — 2,420 — — — 2,420 Other comprehensive income, net of tax— — — — 50 — 50 Net income— — — — — 19,668 19,668 Balance at September 30, 2025105,124 $139 $933,613 $(923,290)$2,341 $619,099 $631,902 

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

Common StockAdditionalPaid-inCapitalTreasury StockAccumulatedOtherComprehensiveIncome (Loss)Retained EarningsTotalStockholders’EquitySharesAmountBalance at December 31, 2023103,405 $133 $738,515 $(635,078)$609 $402,526 $506,